“A successful End-of-Phase 2 FDA meeting for our

“A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich

Sorry I miss quoted. Not happy. Enormous possibilities.